Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1562-1564

  Schleich, Florence ^a   Corhay, Jean Louis ^a   Louis, Renaud ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; BIOLOGICAL MARKER;

AREA UNDER THE CURVE; BLOOD SAMPLING; BRONCHIAL EOSINOPHILIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COPD ASSESSMENT TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; EOSINOPHIL COUNT; EOSINOPHILIA; EXHALED NITRIC OXIDE FRACTION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPIROMETRY; SPUTUM LEVEL; BLOOD; EOSINOPHIL; FORECASTING; LEUKOCYTE COUNT;

BIOMARKERS; EOSINOPHILS; FORECASTING; HUMANS; LEUKOCYTE COUNT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84969872387     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01659-2015     Document Type: Letter

References (13)

1. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD002991.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. Bethesda, National Institutes of Health, 2001.
3. Moermans C, Heinen V, Nguyen M, et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine 2011; 56: 298-304.
4. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2000; 356: 1480-1485.
5. Louis RE, Cataldo D, Buckley MG, et al. Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J 2002; 20: 325-331.
6. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198.
7. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007; 29: 906-913.
8. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697-1700.
9. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
10. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 523-525 .
11. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
12. Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
13. Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count 3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039-1044.